Published By: Editors at Haaretz
Publish Date: January 14, 2025
Targeted cancer treatments are currently considered the hottest field in the biotech world. NanoGhost, an Israeli biotech company, brings one of the most innovative solutions in this field. NanoGhost develops a highly selective first-in-class drug targeting platform (NanoGhosts/NGs) from the cell membrane of mesenchymal stem cells (MSCs), cells with known tropism to cancer and sites of inflammation. NGs act as a “Trojan horse”, penetrating the cancer cells and destroying them with increased efficiency.
Cancer is the leading cause of death in Israel for both men and women, and one of the leading causes of death in the Western world. In light of this tragic fact, cancer research is considered particularly active, and in recent years it is focused on targeted therapies — treatments that aim to more effectively attack cancer cells while reducing general systemic damage, as occurs with broad-spectrum chemotherapy treatments that harm other body organs.
NanoGhost, an Israeli biotech company, introduces one of the most exciting and promising technologies of recent years in this field. NanoGhost develops a highly selective first-in-class drug targeting platform (NanoGhosts/NGs) from the cell membrane of mesenchymal stem cells (MSCs), cells with known tropism to cancer and sites of inflammation. NGs are equipped with the MSCs inherent ability to target cancer, can be loaded with a variety of drugs such as small molecules, proteins, mRNA or other nucleic acids. The entrepreneur who conceived this revolutionary technology is Prof. Marcelle Machluf, the outgoing dean of the Faculty of Biotechnology and Food Engineering at the Technion and a leading researcher in the fields of drug delivery, gene therapy and tissue engineering
Click here to read the full article